MCID: LNG031
MIFTS: 51

Lung Benign Neoplasm

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Lung Benign Neoplasm

MalaCards integrated aliases for Lung Benign Neoplasm:

Name: Lung Benign Neoplasm 12 15
Lung Neoplasms 44 70
Tumor of the Lung 12
Lung Tumor 54

Classifications:



External Ids:

Disease Ontology 12 DOID:3683
MeSH 44 D008175
NCIt 50 C3200
SNOMED-CT 67 126713003
UMLS 70 C0024121

Summaries for Lung Benign Neoplasm

MalaCards based summary : Lung Benign Neoplasm, also known as lung neoplasms, is related to lung adenoma and carcinoid syndrome, and has symptoms including hemoptysis An important gene associated with Lung Benign Neoplasm is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are Pathways in cancer and Gastric cancer. The drugs Epinephrine and Racepinephrine have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and lymph node, and related phenotypes are Reduced mammosphere formation and homeostasis/metabolism

Related Diseases for Lung Benign Neoplasm

Diseases related to Lung Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 792)
# Related Disease Score Top Affiliating Genes
1 lung adenoma 31.6 TP53 SFTPC SCGB1A1 RARB KRAS HRAS
2 carcinoid syndrome 31.5 SYP ENO2 CHGA
3 granular cell tumor 31.0 SYP NKX2-1 ENO2
4 glomus tumor 30.8 TP53 SYP ENO2 CDKN2A
5 desmoplastic small round cell tumor 30.7 SYP ENO2 CHGA
6 perivascular epithelioid cell tumor 30.7 SYP NKX2-1 CDKN2A
7 pulmonary sclerosing hemangioma 30.6 SYP NKX2-1 KRT7 ENO2 CHGA
8 rhabdoid cancer 30.5 TP53 SYP CDKN2A
9 sclerosing hemangioma 30.5 SYP NKX2-1 KRT7 ENO2 CHGA
10 malignant peripheral nerve sheath tumor 30.5 TP53 KRT7 EGFR CDKN2A
11 benign mesothelioma 30.5 NKX2-1 KRT7 KRT20 CDKN2A
12 myoblastoma 30.4 SYP ENO2
13 oncocytoma 30.4 SYP NKX2-1 KRT7 KRT20
14 hemangioblastoma 30.4 SYP ENO2 EGFR
15 pleomorphic rhabdomyosarcoma 30.3 TP53 SYP KRT7
16 epithelial-myoepithelial carcinoma 30.3 TP53 KRT7 HRAS
17 myoepithelial carcinoma 30.3 TP53 KRT7 HRAS
18 neuroendocrine tumor 30.3 SYP NKX2-1 KRT20 HRAS GRP ENO2
19 hemangioma 30.3 TP53 SYP NKX2-1 KRT7 KRAS ENO2
20 paraganglioma 30.2 SYP GRP ENO2 CHGA
21 pleomorphic adenoma 30.2 TP53 KRT7 HRAS CDKN2A
22 squamous cell papilloma 30.2 TP53 HRAS CDKN2A
23 myoma 30.2 TP53 KRAS EGFR
24 papillary adenocarcinoma 30.2 TP53 NKX2-1 KRT7
25 adenocarcinoma in situ 30.2 KRT7 KRT20 KRAS EGFR CDKN2A
26 pleural cancer 30.2 TP53 EGFR CDKN2A
27 alveoli adenoma 30.2 SFTPC SCGB1A1 NKX2-1
28 lymphoepithelioma-like carcinoma 30.2 KRT7 KRT20 ENO2 EGFR
29 tuberous sclerosis 30.1 TP53 SYP STK11 ENO2 CHGA
30 thymoma 30.1 TP53 SYP NKX2-1 HRAS EGFR
31 cystadenoma 30.1 SYP KRT7 KRT20 CHGA
32 appendix adenocarcinoma 30.1 SYP KRT7 KRT20 KRAS HRAS CHGA
33 skin benign neoplasm 30.1 KRT7 KRT20 HRAS ENO2
34 mucinous adenocarcinoma 30.1 TP53 NKX2-1 KRT7 KRT20 KRAS EGFR
35 in situ carcinoma 30.1 TP53 HRAS EGFR CDKN2A
36 neuroendocrine carcinoma 30.1 SYP NKX2-1 KRT7 KRT20 GRP ENO2
37 lung disease 30.1 TP53 SFTPC SCGB1A1 NKX2-1 GRP ENO2
38 exanthem 30.1 KRAS HRAS EGFR
39 mediastinal cancer 30.1 SYP NKX2-1 KRT7 ENO2 CHGA
40 sweat gland cancer 30.1 TP53 SYP KRT7 KRT20
41 bronchus cancer 30.0 GRP FHIT ENO2
42 carcinosarcoma 30.0 TP53 KRT7 KRAS HRAS EGFR CDKN2A
43 pulmonary adenocarcinoma in situ 30.0 SFTPC NKX2-1 KRAS HRAS EGFR
44 mucoepidermoid carcinoma 30.0 TP53 NKX2-1 KRT7 EGFR CHGA CDKN2A
45 kidney rhabdoid cancer 30.0 SYP ENO2
46 chordoma 30.0 TP53 KRT7 EGFR CDKN2A
47 transverse colon cancer 30.0 KRT7 KRT20 KRAS HRAS
48 malignant pheochromocytoma 30.0 SYP ENO2 CHGA
49 large cell neuroendocrine carcinoma 30.0 SYP NKX2-1 KRT7 KRT20 ENO2 EGFR
50 suppression of tumorigenicity 12 29.9 TP53 SYP HRAS EGFR CHGA CDKN2A

Graphical network of the top 20 diseases related to Lung Benign Neoplasm:



Diseases related to Lung Benign Neoplasm

Symptoms & Phenotypes for Lung Benign Neoplasm

UMLS symptoms related to Lung Benign Neoplasm:


hemoptysis

GenomeRNAi Phenotypes related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CHGA EGFR HRAS KRAS KRT7 NQO1

MGI Mouse Phenotypes related to Lung Benign Neoplasm:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.33 CDKN2A CHGA EGFR FHIT GRP HRAS
2 growth/size/body region MP:0005378 10.32 CDKN2A CHGA EGFR ENO2 GRP HRAS
3 cardiovascular system MP:0005385 10.31 CDKN2A CHGA EGFR GRP HRAS KRAS
4 cellular MP:0005384 10.3 CDKN2A EGFR ENO2 KRAS KRT7 NKX2-1
5 mortality/aging MP:0010768 10.28 CDKN2A CHGA EGFR FHIT HRAS KRAS
6 endocrine/exocrine gland MP:0005379 10.27 CDKN2A CHGA EGFR HRAS KRAS MGMT
7 digestive/alimentary MP:0005381 10.21 CDKN2A EGFR FHIT HRAS KRAS NKX2-1
8 neoplasm MP:0002006 10.18 CDKN2A EGFR FHIT HRAS KRAS MGMT
9 nervous system MP:0003631 10.13 CDKN2A CHGA EGFR ENO2 GRP HRAS
10 muscle MP:0005369 10.01 CDKN2A CHGA EGFR HRAS KRAS RARB
11 no phenotypic analysis MP:0003012 9.96 CDKN2A CHGA EGFR HRAS KRAS MGMT
12 normal MP:0002873 9.85 EGFR HRAS KRAS NKX2-1 RARB RASSF1
13 renal/urinary system MP:0005367 9.61 CHGA EGFR HRAS KRAS KRT7 RARB
14 respiratory system MP:0005388 9.44 CDKN2A EGFR ENO2 GRP HRAS KRAS

Drugs & Therapeutics for Lung Benign Neoplasm

Drugs for Lung Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 717)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
2
Racepinephrine Approved Phase 4 329-65-7 838
3
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
4
Terbutaline Approved Phase 4 23031-25-6 5403
5
Ipratropium Approved, Experimental Phase 4 60205-81-4, 22254-24-6 43232 657309
6
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
7
Dalteparin Approved Phase 4 9005-49-6
8
Heparin Approved, Investigational Phase 4 9005-49-6 772 9812414
9
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
10
Remifentanil Approved Phase 4 132875-61-7 60815
11
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
12
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263
13
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
14
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
15
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
16
Lactitol Approved, Investigational Phase 4 585-86-4 157355
17
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
18
Desflurane Approved Phase 4 57041-67-5 42113
19
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
20
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585 135398745
21
Tropisetron Approved, Investigational Phase 4 89565-68-4, 105826-92-4 5595
22
Acetaminophen Approved Phase 4 103-90-2 1983
23
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
24
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
25
Osimertinib Approved Phase 4 1421373-65-0 71496458
26
afatinib Approved Phase 4 850140-72-6, 439081-18-2 10184653
27
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
28
Vemurafenib Approved Phase 4 918504-65-1 42611257 23252090
29
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
30
Imidacloprid Vet_approved Phase 4 105827-78-9 86418
31 Epinephryl borate Phase 4
32 Adrenergic alpha-Agonists Phase 4
33 Adrenergic Agents Phase 4
34 Adrenergic Agonists Phase 4
35 Heparin, Low-Molecular-Weight Phase 4
36 calcium heparin Phase 4
37 Opiate Alkaloids Phase 4
38 N-Methylaspartate Phase 4
39 Dopamine Uptake Inhibitors Phase 4
40 Anesthetics, Dissociative Phase 4
41
Bilirubin Phase 4 635-65-4 5280352
42 N-monoacetylcystine Phase 4
43 Anesthetics, Inhalation Phase 4
44 Platelet Aggregation Inhibitors Phase 4
45 Antipsychotic Agents Phase 4
46 Anesthetics, Intravenous Phase 4
47 Anesthetics, General Phase 4
48 Endostatins Phase 4 71581480
49 Ibandronic Acid Phase 4
50
L-Alanine Nutraceutical Phase 4 56-41-7 5950

Interventional clinical trials:

(show top 50) (show all 5405)
# Name Status NCT ID Phase Drugs
1 The Exploratory Clinical Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin (Endostar) for Local Advanced Non-small Cell Lung Cancer (NSCLC (Ⅲ A / Ⅲ B) ) Unknown status NCT01211002 Phase 4 radiotherapy / EP combined with recombinant human endostatin
2 Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer: a Multi-center, Randomized, Open Label Study Unknown status NCT02348450 Phase 4 Irinotecan;Etoposide;Cisplatin
3 The Randomized Controlled Clinical Trial of Kushen Injection Reducing Radiotherapy Related Adverse Reactions in Lung Cancer Unknown status NCT02346318 Phase 4 Compound Kushen Injection
4 Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research Unknown status NCT02513355 Phase 4 Changchun marina;cisplatin;Taxol;parapl
5 Efficacy of Nebulized Pulmicort Respules on Post Operation Pulmonary Complication During Pulmonary Single Lobectomy Surgery in Primary Lung Cancer Patients With COPD Unknown status NCT02504801 Phase 4 Budesonide
6 Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride in in Combination With EC/EP Unknown status NCT03890055 Phase 4 Anlotinib Hydrochloride
7 A Study of Endostar in Combination With Chemotherapy Followed by Endostar Maintenance Therapy in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01028729 Phase 4 Endostar;Gemcitabine-Cisplatin chemotherapy
8 PET/CT and Roentgen in Lung Cancer. Evaluation of Patients in General Practice Unknown status NCT00675168 Phase 4
9 A Randomized,Double-blind,Placebo-Controlled,Multicenter Clinical Trail of Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT02195453 Phase 4 Yangzhengxiaoji Capsule;Placebo Capsule
10 Maintenance Gemcitabine or Best Supportive Care for the Chinese Advanced NSCLC Patients Without Progression Disease After Given Four Cycles of the Induction Chemotherapy With Gemcitabine Plus Cisplatin Unknown status NCT01336192 Phase 4 Gemcitabine;Best supportive care
11 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Untreated Advanced Non-small-cell Lung Cancer: a Randomized, Open-label Study Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
12 Safety Evaluation of Dexmedetomidine Monitored Anesthesia Care for Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Unknown status NCT01381627 Phase 4 Remifentanil;Dexmedetomidine
13 Randomised, Controlled Study Comparing Chemotherapy Plus Intercalated EGFR-Tyrosine Kinase Inhibitors Combination Therapy With EGFR-Tyrosine Kinase Inhibitors Alone Therapy as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
14 A Double-blind, Randomized, Placebo-controlled Study to Compare the Effectiveness of IV Acetaminophen Administered Intra-operatively in Reducing the Use of Opiates to Treat Post-operative Pain Completed NCT01783236 Phase 4 IV Acetaminophen;Saline Placebo
15 A Single Arm, Open Label, Perspective Study to Determine the Efficacy and Safety of Icotinib Combine Cryotherapy for Advanced NSCLC Patients Completed NCT02744664 Phase 4 Icotinib
16 Medical and Economic Evaluation of FORESEAL Versus the Current Therapeutic Approach (Stapling Alone or Associated With Tissue Sealant) in Terms of Air Leakage Duration After Lung Resection for Cancer. Completed NCT00925444 Phase 4
17 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
18 "Red Morphine Drops" for Symptomatic Treatment of Dyspnoea in Terminal Patients With Primary Lung Cancer or Lung metastases-a Pilot Study Completed NCT00338481 Phase 4 Morphine p.o.;Morphine s.c.
19 Clinical Study of Recombinant Human Endostatin Combined With NP Chemotherapy in the Treatment of Stage ⅢA Non Small Cell Lung Cancer Completed NCT02497118 Phase 4 Endostatin;Vinorelbine;Cisplatin
20 ONCOXIN® and Quality of Life in Cancer Patients in a Real World Setting Study Completed NCT03550482 Phase 4
21 A Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemo-naive, Advanced, Non-Small-Cell Lung Cancer Patients Aged 70 Years or Older in Taiwan Completed NCT01196078 Phase 4 erlotinib [Tarceva];vinorelbine
22 Effect Of Ketamine Infusion On Oxygenation And Ventilation Mechanics In Patients With Chronic Obstructive Pulmonary Disease Applied One Lung Ventilation Completed NCT02962999 Phase 4 Ketamine;Saline
23 Phase IV/II Open-label Study to Evaluate Prompt Response to Treatment With Cisplatin, Gemcitabine and Bevacizumab in Patients With Non-small Lung Cancer. Completed NCT02316327 Phase 4 gemcitabine, cisplatin and bevacizumab
24 A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01066884 Phase 4 erlotinib [Tarceva]
25 Evaluation of the Usefulness of DurogesicD-TRANS for Pain Treatment in Lung Cancer Patients Completed NCT01060137 Phase 4 fentanyl matrix
26 Anesthesia in Flexible Bronchoscopy for Lung Cancer Diagnostic Completed NCT00440960 Phase 4 propofol;midazolam;alfentanil;lidocaine
27 Open-Label Single-Arm Phase IV Study of Pemetrexed in Taiwanese Patients With Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy Completed NCT00380718 Phase 4 pemetrexed
28 Safety of Low Dose Intravenous Contrast 64 Multi-Detector Computed Tomography Scanning in Patients With Chronic Kidney Disease Completed NCT02476526 Phase 4 Low Volume iso-osmolar non-ionic radio contrast medium;Acetylcysteine Inhalation;Sodium Bicarbonate Solution
29 A Prospective, Multicenter, Phase-IV Clinical Trial to Assess Safety of Osimertinib in Indian Adult Patients With Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-positive Non-small Cell Lung Cancer (NSCLC). Completed NCT03853551 Phase 4 Osimertinib
30 Open-label Study of Bevacizumab (AVASTIN®) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer Completed NCT00451906 Phase 4 Platinum-based chemotherapy;Bevacizumab [Avastin]
31 A Pilot Study of the Effects of Neutropenia on Patient Reported Outcomes During Chemotherapy With or Without Neulasta® (Pegfilgrastim) in Subjects With Advanced NSCLC Completed NCT00115206 Phase 4 Neulasta® (pegfilgrastim)
32 A Dual-Cohort, Prospective, Observational Study of Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer Patients With and Without Bone Metastasis Completed NCT00099541 Phase 4 zoledronic acid
33 Phase IV Randomized Trial of Pemetrexed Followed by Docetaxel or in Reverse Sequence in Non-small-cell Lung Cancer Patients Failed Previous Chemotherapy Completed NCT01442909 Phase 4 Docetaxel and pemetrexed
34 A Multi-centre, Open-label, Phase IV, Interventional Study to Evaluate the Efficacy of Erlotinib (Tarceva®) Following 4 Cycles of Platinum-based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Chemotherapy Completed NCT01230710 Phase 4 Erlotinib
35 Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung Cancer - A Randomized, Controlled Trial Completed NCT01741506 Phase 4 Dalteparin (Fragmin®)
36 Safety Study of Nivolumab for Selected Advanced Malignancies in India Completed NCT03444766 Phase 4 Nivolumab
37 A Placebo-Controlled, Multicentre, Randomised, Parallel Group, Trial to Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (StageIIIB/IV) Non Small Cell Lung Cancer (NSCLC) Chinese Patients Who HaveNot Experienced Disease Progression or Unacceptable Toxicity During Front Line Standard Platinum-Based Chemotherapy Completed NCT00770588 Phase 4 Gefitinib;Placebo
38 A Multi-center Observational Clinical Study of Screening of Non-small-cell Lung Cancer With Bone Metastasis and Efficacy and Safety of Those Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
39 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
40 A Multi-centric, Open-label, Phase II Study Investigating the Combination of Afinitor With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced (Stage IV) Large Cell Lung Cancer With Neuroendocrine Differentiation (LC-NEC) Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
41 A Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Completed NCT01287754 Phase 4 erlotinib [Tarceva]
42 An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer Completed NCT00949910 Phase 4 Erlotinib
43 Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration, Using Rapid On-site Cytological Evaluation, for the Diagnosis of Hilar/Mediastinal Enlarged Lymph Nodes: a Randomized Controlled Trial. Completed NCT01658280 Phase 4
44 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
45 A Study Of Cryospray Ablationtm Using Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung Completed NCT00747773 Phase 4
46 Phase IV Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin in Previously Untreated, Inoperable (Stage IIIa or IIIb) Non-small-cell Lung Cancer Completed NCT00686322 Phase 4 Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
47 An International Expanded Access Clinical Programme With ZD1839 (IRESSATM) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC) China Amendment 1: A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa Completed NCT01000740 Phase 4
48 Multicenter Exploratory Trial of the Safety and Efficacy of Adjuvant Docetaxel and Carboplatin in Patients With Resected Non-small Cell Lung Cancer Completed NCT00883675 Phase 4 Docetaxel-Carboplatin
49 Post-marketing Clinical Trial of Induction Chemotherapy of Pemetrexed Plus Carboplatin Followed by Pemetrexed Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer Completed NCT01020786 Phase 4 Pemetrexed;Carboplatin
50 Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+) Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin

Search NIH Clinical Center for Lung Benign Neoplasm

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Carboplatin
Carmustine
Cholecalciferol
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Etoposide
etoposide phosphate
Ifosfamide
Lomustine
Methotrexate
Methotrexate Sodium
Paclitaxel
Procarbazine
Procarbazine Hydrochloride
Teniposide
Vinblastine
Vinblastine Sulfate

Cochrane evidence based reviews: lung neoplasms

Genetic Tests for Lung Benign Neoplasm

Anatomical Context for Lung Benign Neoplasm

MalaCards organs/tissues related to Lung Benign Neoplasm:

40
Lung, Brain, Lymph Node, Bone, T Cells, Liver, Prostate

Publications for Lung Benign Neoplasm

Articles related to Lung Benign Neoplasm:

(show top 50) (show all 1189)
# Title Authors PMID Year
1
GCDFP-15 positive and TTF-1 negative primary lung neoplasms: a tissue microarray study of 381 primary lung tumors. 61 54
19620839 2009
2
Genetic alterations in K-ras and p53 cancer genes in lung neoplasms from Swiss (CD-1) male mice exposed transplacentally to AZT. 54 61
16395694 2007
3
Expression of matrix metalloproteinases 3, 10 and 11 (stromelysins 1, 2 and 3) and matrix metalloproteinase 7 (matrilysin) by cancer cells in non-small cell lung neoplasms. Clinicopathologic studies. 54 61
16506596 2006
4
Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. 61 54
15547185 2004
5
The utility and limitation of thyroid transcription factor-1 protein in primary and metastatic pulmonary neoplasms. 54 61
15084379 2004
6
Dysregulated secretoglobin expression in human lung cancers. 54 61
12826312 2003
7
[Molecular targetting therapy for non-small-cell lung neoplasms with EGF-R inhibitors]. 61 54
12652739 2003
8
Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas. 54 61
10987260 2000
9
Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors. 54 61
9476905 1998
10
Membrane-bound (MUC1) and secretory (MUC2, MUC3, and MUC4) mucin gene expression in human lung cancer. 54 61
8638091 1996
11
Analysis of K-ras, p53 and c-raf-1 mutations in beryllium-induced rat lung tumors. 54 61
7545909 1994
12
Expression of epidermal growth factor receptor in plutonium-239-induced lung neoplasms in dogs. 61 54
1313613 1992
13
[Usefulness of simultaneous antigenic determination of carcinoembryonic antigen (CEA), ferritin and orosomucoid levels in diagnosis of lung neoplasms]. 61 54
1843646 1991
14
Prognostic factors in patients undergoing pulmonary resection for sarcomatoid carcinomas of the lung. 61
32988810 2021
15
Learning curve of robotic portal lobectomy for pulmonary neoplasms: A prospective observational study. 61
33709571 2021
16
Fetal lung interstitial tumor: An uncommon pediatric pulmonary neoplasm. 61
33687015 2021
17
MRWMDA: A novel framework to infer miRNA-disease associations. 61
33221377 2021
18
DF-MDA: an effective diffusion-based computational model for predicting miRNA-disease association. 61
33429082 2021
19
Quantifying intratumor heterogeneity of lung neoplasms with radiomics. 61
33429143 2021
20
[Comprehensive genomic profiling in large cell neuroendocrine lung cancer: the times they are a-changin'.] 61
33512365 2021
21
Role of Omentin in Obesity Paradox in Lung Cancer. 61
33450975 2021
22
Update on genetically defined lung neoplasms: NUT carcinoma and thoracic SMARCA4-deficient undifferentiated tumors. 61
33409598 2021
23
Preoperative Body Weight and Albumin Predict Survival in Patients With Resectable Lung Neoplasms: Role of COPD. 61
32877328 2021
24
Comparison of preoperative scores predicting outcome in elderly undergoing lung malignancies resection. 61
33447396 2020
25
[Application of liquid biopsy in clinical practice: the importance of a scientific network for effective use of the biomolecular markers in NSCLC patient..] 61
33205777 2020
26
Mucous Gland Adenoma: The Spectrum of Growth Patterns and the Diagnostic Challenges. 61
32909967 2020
27
Surgical Treatment of Bilateral Lung Cancers: Long-Term Outcomes and Prognostic Factors. 61
30991418 2020
28
Predicting MiRNA-disease associations by multiple meta-paths fusion graph embedding model. 61
33087064 2020
29
An Uncommon Lung Neoplasm in a Young Patient: Diagnostic Challenges. 61
33060557 2020
30
Opening and closing the doors of the lockdown in Italy without forgetting lung cancer patients. 61
32728692 2020
31
Primary lung neoplasms presenting as multiple synchronous lung nodules. 61
32878970 2020
32
NEMPD: a network embedding-based method for predicting miRNA-disease associations by preserving behavior and attribute information. 61
32912137 2020
33
Deep-belief network for predicting potential miRNA-disease associations. 61
32866969 2020
34
Angioleiomyoma of the pulmonary artery: a case report and literature review. 61
32859240 2020
35
PD-1/PD-L1 negative schwannoma mimicking obstructive bronchial malignancy: A case report. 61
32510862 2020
36
[The development and validation of risk prediction model for lung cancer: a systematic review]. 61
32268653 2020
37
Diagnostic yield of rapid on-site evaluation transbronchial needle aspiration versus conventional transbronchial needle aspiration: a single center experience. 61
32293166 2020
38
CT Halo sign: A systematic review. 61
32007819 2020
39
SAEROF: an ensemble approach for large-scale drug-disease association prediction by incorporating rotation forest and sparse autoencoder deep neural network. 61
32188871 2020
40
Diffusion-Weighted MR Imaging of Primary and Secondary Lung Cancer: Predictive Value for Response to Transpulmonary Chemoembolization and Transarterial Chemoperfusion. 61
31899107 2020
41
Psychosocial interventions for informal caregivers of lung cancer patients: A systematic review. 61
31701588 2020
42
Alternative and New Radiopharmaceutical Agents for Lung Cancer. 61
31868150 2020
43
Modern radiopharmaceuticals for lung cancer imaging with positron emission tomography/computed tomography scan: A systematic review. 61
33062275 2020
44
Chance to rein in a cancer--Spontaneous regression of lung carcinoma (1988-2018): a 30-year perspective. 61
32509094 2020
45
A Rare Cause of Cough: Tracheobronchial Myxoid Spindle Cell Lipoma. 61
32551146 2020
46
Classification and Imaging Findings of Lung Neoplasms. 61
31964479 2020
47
mTOR in Lung Neoplasms. 61
32016810 2020
48
CT-based radiomics for prediction of histologic subtype and metastatic disease in primary malignant lung neoplasms. 61
31722085 2020
49
A Computational Study of Potential miRNA-Disease Association Inference Based on Ensemble Learning and Kernel Ridge Regression. 61
32117922 2020
50
Bronchial Carcinoid Tumors with Massive Osseous Metaplasia: A Case Report and Review of the Literature. 61
30977863 2020

Variations for Lung Benign Neoplasm

Expression for Lung Benign Neoplasm

Search GEO for disease gene expression data for Lung Benign Neoplasm.

Pathways for Lung Benign Neoplasm

Pathways related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1 12.58 TP53 RASSF1 RARB NQO1 KRAS HRAS
2
Show member pathways
12.53 TP53 RARB NQO1 KRAS HRAS EGFR
3
Show member pathways
12.39 TP53 STK11 KRAS HRAS EGFR
4 12.37 TP53 RASSF1 KRAS HRAS EGFR CDKN2A
5
Show member pathways
12.36 TP53 RASSF1 RARB KRAS HRAS FHIT
6 12.27 TP53 KRAS HRAS CDKN2A
7 12.23 TP53 KRAS HRAS EGFR
8 12.22 TP53 KRAS HRAS CDKN2A
9
Show member pathways
12.22 TP53 KRAS HRAS EGFR
10 12.08 TP53 KRAS HRAS CDKN2A
11 12.06 TP53 STK11 KRAS EGFR
12
Show member pathways
12.03 TP53 STK11 KRAS HRAS
13
Show member pathways
11.99 TP53 KRAS HRAS EGFR
14
Show member pathways
11.97 STK11 KRAS HRAS EGFR
15 11.86 TP53 KRAS HRAS CDKN2A
16 11.63 TP53 KRAS HRAS
17 11.58 TP53 KRAS HRAS EGFR
18 11.54 KRAS HRAS EGFR
19 11.48 TP53 EGFR CDKN2A
20 11.48 TP53 MGMT KRAS HRAS EGFR CDKN2A
21 11.37 KRAS HRAS EGFR
22 11.35 NQO1 KRAS HRAS EGFR
23 11.16 KRAS HRAS EGFR
24 11.08 RASSF1 KRAS EGFR
25
Show member pathways
11.05 KRAS HRAS EGFR
26 10.96 TP53 RASSF1 KRAS HRAS EGFR CDKN2A

GO Terms for Lung Benign Neoplasm

Biological processes related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.88 TP53 NKX2-1 KRAS HRAS CDKN2A
2 negative regulation of cell proliferation GO:0008285 9.85 TP53 STK11 RARB HRAS CDKN2A
3 apoptotic process GO:0006915 9.85 TP53 STK11 KRT20 HRAS FHIT CDKN2A
4 positive regulation of MAP kinase activity GO:0043406 9.58 KRAS HRAS EGFR
5 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.49 TP53 EGFR
6 response to isolation stress GO:0035900 9.43 KRAS HRAS
7 intrinsic apoptotic signaling pathway by p53 class mediator GO:0072332 9.43 TP53 STK11 FHIT
8 cell cycle arrest GO:0007050 9.35 TP53 STK11 RASSF1 HRAS CDKN2A
9 regulation of long-term neuronal synaptic plasticity GO:0048169 9.33 SYP KRAS HRAS
10 positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway GO:1900738 9.32 GRP CHGA
11 Ras protein signal transduction GO:0007265 9.02 TP53 RASSF1 KRAS HRAS CDKN2A

Molecular functions related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.56 TP53 SYP SFTPC RASSF1 NQO1 KRAS
2 p53 binding GO:0002039 9.33 TP53 STK11 CDKN2A
3 MDM2/MDM4 family protein binding GO:0097371 9.26 TP53 CDKN2A
4 LRR domain binding GO:0030275 8.62 STK11 KRAS

Sources for Lung Benign Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....